Zydus Lifesciences Acquires Exclusive Licensing Rights for Next Gen Immuno-Oncology Platforms from Agenus Inc., USA

Zydus Lifesciences Ltd. has entered into a definitive exclusive licensing agreement with Agenus Inc., USA to acquire commercial rights for its investigational Botensilimab (BOT) and Balstilimab (BAL), combination therapy for the territories of India and Sri Lanka. The company will be responsible for clinical development and regulatory approvals of licensed products in these territories and will pay royalty on net sales upon successful approval & commercialization to Agenus Inc., USA. The lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.